Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Ponatinib 2-Year Efficacy, Safety and Health-Related Quality of Life in Patients with Philadelphia Chromosome-Positive Leukemia: An Open-Label, Multicenter, Phase 2 Clinical Trial in China

Blood (2024) 144 (Supplement 1): 6602.

https://doi.org/10.1182/blood-2024-208258

Published: 2024

Journal Articles

Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R T618I : A Multi-Centre Retrospective Study

Blood (2024) 144 (Supplement 1): 1793.

https://doi.org/10.1182/blood-2024-207591

Published: 2024

Journal Articles

Analysis of the Impact of TKI Dose Adjustment Under the Guidance of Blood Concentration Monitoring on the Efficacy, Safety and Quality of Life in Patients with CML

Zherou He, Qing Zhang, Xuan Zhou, Qiang Wang, Xiaoli Liu, Na Xu

Blood (2024) 144 (Supplement 1): 1773.

https://doi.org/10.1182/blood-2024-207302

Published: 2024

Journal Articles

The Efficacy and Safety of Selinexor Plus Ruxolitinib Regimen in Ruxolitinib-Resistant Myelofibrosis: A Retrospective Study

Ziyu Wen, Xuan Zhou, Bingyu Lin, Xiaoli Liu, Qiang Wang, Na Xu

Blood (2024) 144 (Supplement 1): 1803.

https://doi.org/10.1182/blood-2024-205725

Published: 2024

Journal Articles

Clinical Characteristics and Risk Factors of Chronic Kidney Disease Among Patients with Myeloproliferative Neoplasms

Zicheng Gao, Xuan Zhou, Qiang Wang, Dan Xu, Xiaoli Liu, Na Xu, Qifa Liu

Blood (2024) 144 (Supplement 1): 6643.

https://doi.org/10.1182/blood-2024-207289

Published: 2024

Journal Articles

Safety and Efficacy of Luspatercept for the Treatment of Refractory Anemia in Patients with Myelofibrosis

Ziyu Wen, Xuan Zhou, Bingyu Lin, Xiaoli Liu, Qiang Wang, Na Xu

Blood (2024) 144 (Supplement 1): 6639.

https://doi.org/10.1182/blood-2024-205673

Published: 2024

Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Blood (2024) 144 (18): 1951–1961.

https://doi.org/10.1182/blood.2024024761

Published: 2024

Includes: Supplemental data

Journal Articles

A Predictive Scoring System for Therapy Failure of Tyrosine-Kinase Inhibitors in Patients with Chronic-Phase Chronic Myeloid Leukemia

Xiao-shuai Zhang, Bingcheng Liu, Jian Huang, Xin Du, Yanli Zhang, Na Xu, Xiaoli Liu, Li Weiming, Hai Lin, Huanling Zhu, Yunfan Yang, Ling Pan, Xiao-jun Huang, Qian Jiang

Blood (2023) 142 (Supplement 1): 3167.

https://doi.org/10.1182/blood-2023-185473

Published: 2023

Journal Articles

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Blood (2023) 142 (Supplement 1): 869.

https://doi.org/10.1182/blood-2023-187740

Published: 2023

Journal Articles

Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study

Ziyu Wen, Zhiping Fan, Qiang Wang, Xuan Zhou, Zherou He, Zicheng Gao, Hong Chen, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Hongsheng Zhou, Qifa Liu, Na Xu

Blood (2023) 142 (Supplement 1): 4538.

https://doi.org/10.1182/blood-2023-181850

Published: 2023

Journal Articles

Ruxolitinib or Interferon-α Treatment As a Protective Strategy for Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN) during the COVID-19 Pandemic

Zicheng Gao, Zherou He, Xuan Zhou, Ziyu Wen, Hong Chen, Qiang Wang, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Qifa Liu, Na Xu

Blood (2023) 142 (Supplement 1): 6411.

https://doi.org/10.1182/blood-2023-184700

Published: 2023

Journal Articles

CD19-Specific CAR NK Cells Coexpressing IL-21 Exhibit Superior Expansion and Antitumor Activity Against CD19-Postive Lymphoma

Bailin He, Hong Chen, Shikai Deng, Chengyao Li, Na Xu, Xiaoli Liu, Hongsheng Zhou, Qifa Liu

Blood (2023) 142 (Supplement 1): 6824.

https://doi.org/10.1182/blood-2023-178289

Published: 2023

Journal Articles

Analysis the Relationship between Clonal Hematopoiesis and Cardiovascular Events in Chronic Myeloid Leukemia Based on Next-Generation Sequencing Technology

Jie Luo, Ziyu Wen, Mengxia Zhao, Zicheng Gao, Hong Chen, Qiang Wang, Xuan Zhou, Zherou He, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Qifa Liu, Na Xu

Blood (2023) 142 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2023-182007

Published: 2023

Journal Articles

Flumatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: An Open-Label, Multi-Center Study

Blood (2023) 142 (Supplement 1): 3175.

https://doi.org/10.1182/blood-2023-181456

Published: 2023

Journal Articles

Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement

Bailin He, Hongsheng Zhou, Ren Lin, Zhixiang Wang, Na Xu, Qiang Wang, Jing Sun, Xiaoli Liu, Peng Li, Qifa Liu

Blood (2023) 142 (Supplement 1): 3484.

https://doi.org/10.1182/blood-2023-184492

Published: 2023

Journal Articles

Single-Cell RNA Sequencing Uncovers Abnormal Differentiation of Neutrophil and Megakaryocyte Might Mediated Ruxolitinib Resistance for Patinets with PMF

Na Xu, Hanyin Liang, Dongmei Luo, Ziyu Wen, Zicheng Gao, Zherou He, Hong Chen, Xiaoli Liu, Qifa Liu

Blood (2023) 142 (Supplement 1): 6341.

https://doi.org/10.1182/blood-2023-184551

Published: 2023

Journal Articles

Flumatinib for the Treatment of Adult Patients with Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia: Results from Real-World Data

Xuan Zhou, Na Xu, Ziyu Wen, Hanyin Liang, Dongmei Luo, Hong Chen, Zherou He, Zicheng Gao, Qiang Wang, Dan Xu, Xiaoli Liu, Qifa Liu

Blood (2023) 142 (Supplement 1): 6379.

https://doi.org/10.1182/blood-2023-184643

Published: 2023

Journal Articles

TKI Dose Optimization Based on Therapeutic Drug Monitoring（TDM) with Encouraging Outcomes and Well-Tolerated for Chronic Myeloid Leukaemia Patients

Zherou He, Xuan Zhou, Ziyu Wen, Zicheng Gao, Hong Chen, Qiang Wang, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Na Xu, Qifa Liu

Blood (2023) 142 (Supplement 1): 1807.

https://doi.org/10.1182/blood-2023-182765

Published: 2023

Journal Articles

Single-Cell RNA Profiling of Primary Myelofibrosis Reveals RUX Resistance Decreasing Mononuclear Phagocytes in Peripheral Blood

Luo Dongmei, Na Xu, Xiaoli Liu, Jie Luo, Hanyin Liang, Zherou He, Hong Chen, Qiang Wang, Xuan Zhou

Blood (2022) 140 (Supplement 1): 6755–6756.

https://doi.org/10.1182/blood-2022-165137

Published: 2022

Journal Articles

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Blood (2022) 140 (Supplement 1): 3891–3894.

https://doi.org/10.1182/blood-2022-168812

Published: 2022

NARROW

Ponatinib 2-Year Efficacy, Safety and Health-Related Quality of Life in Patients with Philadelphia Chromosome-Positive Leukemia: An Open-Label, Multicenter, Phase 2 Clinical Trial in China

Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R T618I : A Multi-Centre Retrospective Study

Analysis of the Impact of TKI Dose Adjustment Under the Guidance of Blood Concentration Monitoring on the Efficacy, Safety and Quality of Life in Patients with CML

The Efficacy and Safety of Selinexor Plus Ruxolitinib Regimen in Ruxolitinib-Resistant Myelofibrosis: A Retrospective Study

Clinical Characteristics and Risk Factors of Chronic Kidney Disease Among Patients with Myeloproliferative Neoplasms

Safety and Efficacy of Luspatercept for the Treatment of Refractory Anemia in Patients with Myelofibrosis

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

A Predictive Scoring System for Therapy Failure of Tyrosine-Kinase Inhibitors in Patients with Chronic-Phase Chronic Myeloid Leukemia

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study

Ruxolitinib or Interferon-α Treatment As a Protective Strategy for Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN) during the COVID-19 Pandemic

CD19-Specific CAR NK Cells Coexpressing IL-21 Exhibit Superior Expansion and Antitumor Activity Against CD19-Postive Lymphoma

Analysis the Relationship between Clonal Hematopoiesis and Cardiovascular Events in Chronic Myeloid Leukemia Based on Next-Generation Sequencing Technology

Flumatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: An Open-Label, Multi-Center Study

Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement

Single-Cell RNA Sequencing Uncovers Abnormal Differentiation of Neutrophil and Megakaryocyte Might Mediated Ruxolitinib Resistance for Patinets with PMF

Flumatinib for the Treatment of Adult Patients with Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia: Results from Real-World Data

TKI Dose Optimization Based on Therapeutic Drug Monitoring（TDM) with Encouraging Outcomes and Well-Tolerated for Chronic Myeloid Leukaemia Patients

Single-Cell RNA Profiling of Primary Myelofibrosis Reveals RUX Resistance Decreasing Mononuclear Phagocytes in Peripheral Blood

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only